Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 13 articles:
HTML format

Single Articles

    April 2023
  1. CHUNG R, McKiernan J, Arpaia N, Marabelle A, et al
    Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
    Eur J Cancer. 2023;187:58-64.
    PubMed     Abstract available

    November 2022
  2. MEYNARD L, Dinart D, Delaunay B, Flechon A, et al
    Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
    Eur J Cancer. 2022;175:43-53.
    PubMed     Abstract available

    October 2022
  3. YOON S, Shin SJ, Kim HC, Kim YS, et al
    Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure.
    Eur J Cancer. 2022;174:81-89.
    PubMed     Abstract available

    June 2022
  4. LIU Z, Jin K, Zeng H, Shao F, et al
    B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Eur J Cancer. 2022;171:133-142.
    PubMed     Abstract available

    May 2022
  5. KLUMPER N, Sikic D, Saal J, Buttner T, et al
    C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
    Eur J Cancer. 2022;167:13-22.
    PubMed     Abstract available

    March 2022
  6. SONPAVDE GP, Sternberg CN, Loriot Y, Marabelle A, et al
    Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
    Eur J Cancer. 2022;163:55-65.
    PubMed     Abstract available

    November 2021
  7. SEETHAPATHY H, Street S, Strohbehn I, Lee M, et al
    Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
    Eur J Cancer. 2021;157:50-58.
    PubMed     Abstract available

    July 2021
  8. MORI K, Pradere B, Moschini M, Mostafaei H, et al
    First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Eur J Cancer. 2021;151:35-48.
    PubMed     Abstract available

  9. BOUDIN L, Patient M, Romeo E, Blade JS, et al
    Lurbinectedin for metastatic small-cell bladder carcinoma.
    Eur J Cancer. 2021;151:1-2.

    May 2021
  10. ROUANNE M, Arpaia N, Marabelle A
    CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.
    Eur J Cancer. 2021 May 7. pii: S0959-8049(21)00222.

    March 2021
  11. GROENEVELD CS, Fontugne J, Cabel L, Bernard-Pierrot I, et al
    Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Eur J Cancer. 2021;148:181-189.
    PubMed     Abstract available

  12. BAART VM, van der Horst G, Deken MM, Bhairosingh SS, et al
    A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
    Eur J Cancer. 2021;146:11-20.
    PubMed     Abstract available

    May 2020
  13. MATSUMOTO S, Kijima T, Matsuoka Y, Yamamoto M, et al
    A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
    Eur J Cancer. 2020;131:104-107.

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.